全文获取类型
收费全文 | 428篇 |
免费 | 14篇 |
国内免费 | 38篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 21篇 |
妇产科学 | 2篇 |
基础医学 | 30篇 |
口腔科学 | 1篇 |
临床医学 | 25篇 |
内科学 | 79篇 |
皮肤病学 | 12篇 |
神经病学 | 2篇 |
特种医学 | 2篇 |
外科学 | 119篇 |
综合类 | 69篇 |
预防医学 | 10篇 |
眼科学 | 7篇 |
药学 | 94篇 |
中国医学 | 2篇 |
肿瘤学 | 4篇 |
出版年
2023年 | 2篇 |
2022年 | 14篇 |
2021年 | 18篇 |
2020年 | 9篇 |
2019年 | 17篇 |
2018年 | 12篇 |
2017年 | 7篇 |
2016年 | 19篇 |
2015年 | 12篇 |
2014年 | 26篇 |
2013年 | 33篇 |
2012年 | 18篇 |
2011年 | 26篇 |
2010年 | 21篇 |
2009年 | 29篇 |
2008年 | 29篇 |
2007年 | 30篇 |
2006年 | 31篇 |
2005年 | 31篇 |
2004年 | 27篇 |
2003年 | 13篇 |
2002年 | 22篇 |
2001年 | 15篇 |
2000年 | 12篇 |
1998年 | 5篇 |
1997年 | 1篇 |
1995年 | 1篇 |
排序方式: 共有480条查询结果,搜索用时 15 毫秒
41.
Sharzehi K Huang MA Schreibman IR Brown KA 《Journal canadien de gastroenterologie》2010,24(10):588-592
BACKGROUND:
Autoimmune hepatitis is characterized by hepatocellular inflammation often progressing to cirrhosis. Standard treatment consists of corticosteroids and azathioprine. For the 20% of patients with refractory disease or those who are intolerant to medication, there is no standardized treatment.OBJECTIVE:
To evaluate mycophenolate mofetil (MMF) as an alternative therapy for autoimmune hepatitis.METHODS:
The present retrospective study identified all patients with autoimmune hepatitis who were treated with MMF over a 10-year period at the Henry Ford Hospital (Michigan, USA). These patients were evaluated for tolerance and response.RESULTS:
Of the 90 patients participating in the study, 48% had a complete response, 32% experienced relapses and 21% were refractory. MMF was initiated in 21 patients – 12 (57%) for refractory disease and nine (43%) for medication intolerance. Of the 12 patients converted for refractory disease, all showed biochemical improvement but none had a complete response. Of the patients converted due to intolerance, 88% maintained complete remission. For all patients converted to MMF, there was a mean decrease in steroid dose from 18.9 mg/day to 7.8 mg/day (P=0.01).CONCLUSIONS:
In patients with autoimmune hepatitis who were intolerant to conventional therapy, MMF was well tolerated, with 88% of patients maintained in remission. MMF did not induce remission in those refractory to conventional therapy; however, it resulted in a significant decrease in steroid use. Prospective studies are needed to better assess the role of MMF as an alternative therapy. 相似文献42.
夏熊芳 《临床合理用药杂志》2012,5(6):39-40
目的比较霉酚酸酯(MMF)与间断环磷酰胺(CTX)静脉冲击疗法治疗狼疮性肾炎(LN)的临床疗效。方法将60例LN患者随机分为MMF治疗组及CTX治疗组,进行相应治疗,两组均联合标准剂量的泼尼松。结果治疗3个月后,MMF组白蛋白、C3升高,差异有统计学意义,而CTX组仅C3改善有统计学意义。3个月时MMF组在提高白蛋白方面与CTX组比较,差异有统计学意义(P<0.01)。治疗6个月后,两组白蛋白、C3均较治疗前升高,差异有统计学意义(P<0.01),MMF组与CTX组比较,差异有统计学意义(P<0.01)。CTX组治疗6个月时的白蛋白较治疗3个月时提高,差异有统计学意义(P<0.05)。结论 MMF组比CTX组疗效好,更具安全性。 相似文献
43.
Craig S. Wong Christopher A. Fink Jane Baechle Alexis A. Harris Amy O. Staples John R. Brandt 《Pediatric nephrology (Berlin, Germany)》2009,24(4):761-767
C1q nephropathy (C1qN) is an uncommon disorder seen in children and adults with nephrotic syndrome and non-specific urinary
findings. It has been described with minimal change nephrotic syndrome (MCNS), focal segmental glomerulonephritis and isolated
mesangial proliferative glomerulonephritis. We describe nine children with MCNS and mesangial C1q deposition. These children
had a median age of 2.7 years at diagnosis (range 1.3–15 years), 56% were male and 78% were Hispanic. We compared these children
to concurrent patients with nephrotic syndrome and biopsy-proven MCNS. We found that the C1qN patients were more likely than
MCNS children to require chronic immunosuppression with calcineurin inhibitors or mycophenolate mofetil to maintain remission.
However, all children were able to achieve and sustain clinical remission of nephrotic syndrome. Children with C1qN and minimal
change histology have an increased frequency of frequently relapsing and steroid-unresponsive disease, but they can attain
prolonged remission and stable renal function with calcineurin inhibitor or mycophenolate mofetil therapy. 相似文献
44.
C1q nephropathy (C1qN) is a rare idiopathic glomerulopathy typically seen in adolescents and young adults. All kidney biopsies
done from 2002 to 2007 were analyzed (264). Thirteen cases of C1qN from 212 (6.6%) native biopsies and one case out of 52
(1.9%) transplant biopsies were reviewed regarding demographic features, clinical presentation, histopathology, treatment,
and outcome. Age varied from 1 to 18 years; half were boys. Ten children (71.4%) presented with nephrotic syndrome (NS). The
most common histopathology found was diffuse mesangial proliferative glomerulonephritis (DMP) by light microscopy (LM), with
diffuse granular staining for C1q predominantly in the mesangium. Children with either NS or persistent gross hematuria received
prednisone and angiotensin-converting enzyme inhibitors (ACEi) (11). Median follow-up was 36 months. Steroid response was
complete in 6 patients (54.5%). Those with steroid resistance (5) or steroid dependence (2) received further immunosuppression
with mycophenolate mofetil (MMF) or tacrolimus (Tac). Three children achieved complete remission and four partial remission.
Frequent relapses were seen in 4/14 patients. Renal survival was 100%. Our report reveals a high incidence of C1qN in pediatric
patients, with variable clinical presentation. Despite a high incidence of steroid resistance among those with NS, an excellent
response was observed with the addition of further immunosuppression. 相似文献
45.
Mycophenolate mofetil reduces disease activity and steroid dosage in Takayasu arteritis 总被引:1,自引:0,他引:1
Mycophenolate mofetil (MMF) has recently been reported as a useful alternative immunosuppressive drug in autoimmune diseases
including in Takayasu arteritis (TA). The aim of this study was to verify the efficacy and tolerability of MMF administration
in controlling TA disease activity and allowing glucocorticosteroid reduction. Ten consecutive active TA patients followed
at the Vasculitis Clinic were enrolled from January 2003 to 2006 and received oral MMF (2 g/day) for an average of 23.3 months.
Disease activity assessed using the National Institutes of Health criteria, clinical features, and inflammatory laboratory
findings were evaluated. Five patients had received at least one immunosuppressive drug before administration of MMF (four
methotrexate, two azathioprine, and one chlorambucil) but had not achieved clinical and laboratory remission. The other five
patients received MMF as their first immunosuppressive drug because of an important disease flare during steroid dose reduction.
Clinical activity disappeared in all patients with MMF therapy, except in one patient who abandoned the study because of an
important headache, attributed to the drug. Moreover, the MMF therapy allowed significant tapering of the prednisone dose
in the rest of the nine patients (24.5 ± 17.1 vs 5.8 ± 7.8 mg/day; p = 0.0019). Reinforcing this finding, a significant reduction in inflammatory laboratory parameters, erythrocyte sedimentation
rate (24.7 ± 15.5 vs 12.8 ± 10.8 mm/h; p = 0.036) and C-reactive protein (24.0 ± 14.9 vs 11.2 ± 10.7 mg/l; p = 0.0167), was observed. In summary, MMF therapy reduced clinical and laboratory parameters of TA disease activity, suggesting
that this drug is a promising immunosuppressive drug, particularly in refractory cases and as a steroid-sparing agent. 相似文献
46.
Aurlie Prmaud Annick Rousseau Gyasi Johnson Cindy Canivet Peggy Gandia Fabrice Muscari Jean Marie Peron Lionel Rostaing Pierre Marquet Nassim Kamar 《Pharmacological research》2011,63(5):432-438
Mycophenolic acid (MPA) plasma concentrations were reported to be associated with a decrease in T-cell proliferation, and in both IL-2 α-chain (CD25) and transferin receptor (CD71) expression. The aim of this study was to confirm, quantify and model these PK/PD relationships.Full profiles of MPA plasma concentrations, T-cell proliferation, intracytoplasmic IL-2 and TNF-α expression, and both CD71 and CD25 expression were collected over the 12 h after dosing in 10 patients on the waiting list for liver transplantation. Data were analyzed using NONMEM®.Both CD25 and CD71 expression and T cell proliferation clearly decreased (median of decrease from baseline 62%, 68% and 94%, respectively) with increasing MPA concentrations, in contrast to IL-2 and TNF-α expression. The CD25 and CD71 baseline expression (E0) and maximum effect (Emax) were correlated with the E0 and Emax values of T-cell proliferation (r2 = 0.509 and r2 = 0.622, respectively). The CD25, CD71 expression and T-cell proliferation profiles were adequately fitted using a sigmoid inhibitory Emax model. Low estimated values (≤2 mg/L) for 50% inhibitory MPA concentrations were obtained. This study confirmed a transient MPA concentration-dependent decrease in T-cells expressing CD25 and CD71 and a strong reduction of T-cell proliferation and showed that CD25 and CD71 expression was correlated with T-cell proliferation. 相似文献
47.
Mycophenolate mofetil versus cyclosporine for remission maintenance in nephrotic syndrome 总被引:1,自引:0,他引:1
Dorresteijn EM Kist-van Holthe JE Levtchenko EN Nauta J Hop WC van der Heijden AJ 《Pediatric nephrology (Berlin, Germany)》2008,23(11):2013-2020
We performed a multi-centre randomized controlled trial to compare the efficacy of mycophenolate mofetil (MMF) to that of
cyclosporine A (CsA) in treating children with frequently relapsing nephrotic syndrome and biopsy-proven minimal change disease.
Of the 31 randomized initially selected patients, seven were excluded. The remaining 24 children received either MMF 1200 mg/m2 per day (n = 12) or CsA 4–5 mg/kg per day (n = 12) during a 12-month period. Of the 12 patients in the MMF group, two discontinued the study medication. Evaluation of
the changes from the baseline glomerular filtration rate showed an overall significant difference in favour of MMF over the
treatment period (p = 0.03). Seven of the 12 patients in the MMF group and 11 of the 12 patients in the CsA group remained in complete remission
during the entire study period. Relapse rate in the MMF group was 0.83/year compared to 0.08/year in the CsA group (p = 0.08). None of the patients reported diarrhea. Pharmacokinetic profiles of mycophenolic acid were performed in seven patients.
The patient with the lowest area under the curve had three relapses within 6 months. In children with frequently relapsing
minimal change nephrotic syndrome, MMF has a favourable side effect profile compared to CsA; however, there is a tendency
towards a higher relapse risk in patients treated with MMF. 相似文献
48.
49.
This review concentrates on autoimmune hepatitis (AIH), a liver disorder affecting both children and adults, characterized by inflammatory liver histology, elevated transaminase levels, circulating non-organ-specific autoantibodies, and increased levels of immunoglobulin G, in the absence of a known aetiology. Two types of AIH are recognized according to seropositivity: smooth muscle antibody and/or antinuclear antibody define AIH type 1, while antibodies to liver-kidney microsome type 1 and/or liver cytosol type 1 define AIH type 2. AIH type 1 affects both adults and children, while AIH type 2 is mainly a paediatric disease, though it does occasionally affects young adults. There is a female predominance in both types. AIH is particularly aggressive in children/adolescents, progressing rapidly unless immunosuppressive treatment is started promptly. With appropriate treatment 80% of patients achieve remission and long-term survival. In childhood/adolescence, sclerosing cholangitis with strong autoimmune features, including interface hepatitis and serological features identical to AIH type 1, is as prevalent as AIH, but it affects boys and girls equally. The differential diagnosis relies on cholangiographic studies. In autoimmune sclerosing cholangitis, liver parenchymal damage responds satisfactorily to immunosuppressive treatment, whereas bile duct disease progresses in 50% of cases, leading to a worse prognosis and higher transplantation requirement; it has a higher recurrence rate after transplant than AIH. AIH can arise de novo in patients transplanted for non-autoimmune liver disease. Post transplant de novo AIH affects children and adults and responds well to the same treatment schedule used for classical AIH, but not to that used for acute rejection. 相似文献
50.
目的探讨霉酚酸酯、缬沙坦及2者联合应用对糖尿病。肾病(DN)大鼠足细胞损伤的保护作用。方法雄性Wistar大鼠行右肾切除后,腹腔注射链脲佐菌素(STZ,65mg/kg)建立糖尿病模型。将实验动物随机分为右。肾切除对照组(NC)、糖尿病组(DM)、霉酚酸酯治疗组(M)、缬沙坦治疗组(V)、缬沙坦和霉酚酸酯联合治疗组(V+M)。治疗组分别给予霉酚酸酯15mg·kg^-1·d^-1,缬沙坦40mg·kg^-1·d^-1;联合治疗组为上述两组之和。检测各组8周末的左肾质量/体质量比值、尿蛋白量(24h)、血糖(Glu)、Scr。光镜及电镜观察肾组织形态学变化。免疫组化检测肾组织中nephrin、结蛋白(desmin)及单核细胞趋化因子1(MCP-1)蛋白表达。实时PCR测定肾组织中nephrin及MCP-1mRNA表达。结果与NC组相比,DM组大鼠血糖、尿蛋白量及左肾质量/体质量比值均显著上升(P〈0.01);肾小球硬化指数(GSI)及肾间质损害加重(P〈0.01);肾组织内MCP-1、desmin蛋白表达均显著上调(P〈0.01)。与DM组比较,M组、V组及V+M组上述指标除Glu、Scr外,均明显改善(P〈0.05或P〈0.01)。与NC组(100%)相比,DM组nephrinmRNA表达下调(78%,P〈0.05);各治疗组nephrinmRNA表达增加,以M组增加最明显(134%,P〈0.01)。与NC组(100%)相比,DM组MCP-1mRNA表达明显上调(251%,P〈0.05);各治疗组明显降低,以M组最显著(126%,P〈0.01)。nephrinmRNA与MCP-1mRNA表达呈负相关(r=-0,86。P〈0.01)。尿蛋白量(24h)与MCP-1mRNA呈正相关fr=0.82,P〈0.01);与nephrinmRNA呈负相关(r=-0.78,P〈0.01)。结论霉酚酸酯及缬沙坦均能下调糖尿病大鼠肾组织中desmin及MCP-1基因及蛋白的表达,上调nephrin基因及蛋白表达,降低尿蛋白量,预防肾损伤。联合治疗不优于单一治疗。霉酚酸酯可能通过抗炎性反应减轻足细胞损伤,减少蛋白尿,对早期DN大鼠具有明显的肾保护作用。 相似文献